Biomerica reported fiscal 2025 results with net sales essentially flat at $5.3 million and a 19% year-over-year improvement in operating loss to $5.1 million, driven by $1.3 million in operating expense reductions and lower cash burn in operating activities. The company highlighted a post–year-end milestone that could reshape its growth trajectory: issuance of an AMA CPT Proprietary Laboratory Analyses code for the InFoods IBS test, alongside a peer-reviewed publication in Gastroenterology, a direct-to-consumer launch with at-home blood self-collection, and initial regional expansion in the Middle East and North Africa.
The strategic question is whether a micro-cap diagnostics company can convert a clinical signal and a billing code into payer-backed scale in a category long clouded by skepticism. The InFoods IBS approach utilizes blood-based immunoreactivity to tailor food avoidance, rather than relying on broad elimination diets. The published data show statistically significant improvements in abdominal pain and bloating compared to a placebo-guided diet. With a PLA code now in place, Biomerica has cleared the first hurdle on the U.S. reimbursement pathway. However, coverage and pricing decisions will require targeted Medical Affairs engagement, utilization evidence in real-world practice, and health economic data that demonstrate reductions in symptom burden, healthcare utilization, and the use of pharmacotherapies.
For Commercial leaders, the near-term levers are clear. The company’s pivot to decentralized access via telehealth and a finger-stick self-collection kit expands reach to IBS patients who typically cycle through lifestyle guidance, over-the-counter options, and off-label treatments. If payers perceive the test as a cost-offset relative to branded IBS therapies, GI procedures, or repeat primary care visits, coverage could accelerate adoption and reduce reliance on cash-pay channels. Conversely, without rapid payer uptake, the go-to-market will hinge on digital acquisition economics, laboratory throughput, and clinician advocacy to validate patient selection and adherence to personalized dietary recommendations.
Medical Affairs teams across the GI ecosystem will watch how evidence generalizes across IBS subtypes and comorbidities and whether outcomes are durable beyond controlled study settings. The path to guideline inclusion will depend on reproducibility, standardized reporting, and pragmatic studies that measure quality-of-life gains and reductions in rescue medications. The company’s EU IVDR certification for food-intolerance diagnostics tied to Crohn’s disease and ulcerative colitis opens a parallel European narrative, though those indications will demand even more rigorous evidence. In H. pylori, evaluations of the HP Detect stool antigen ELISA in the U.S. and Europe could bolster a steadier revenue base; however, differentiation in a mature category will likely come from contract work, turnaround times, and integration with test-and-treat pathways.
The broader context is a diagnostics market recalibrating around decentralized testing, PLA-enabled billing strategies, and value narratives that must resonate with both payers and clinicians. Biomerica’s cost discipline and MENA regulatory wins, including a PSA rapid test approval in the UAE, demonstrate operational focus; however, the growth engine relies on transforming InFoods IBS from a promising offering into a reimbursed standard of care. The next twelve months are pivotal: can coverage policies, RWE, and HEOR coalesce quickly enough to shift revenue mix and margin profile, or will the category remain a niche DTC play vulnerable to payer skepticism and copycats?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
